Amsterdam Neuroscience
-
Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials
Müller, A. R., den Hollander, B., van de Ven, P. M., Roes, K. C. B., Geertjens, L., Bruining, H., van Karnebeek, C. D. M., Jansen, F. E., de Wit, M. C. Y., Ten Hoopen, L. W., Rietman, A. B., Dierckx, B., Wijburg, F. A., Boot, E., Brands, M. M. G. & van Eeghen, A. M., 1 Dec 2024, In: BMC psychiatry. 24, 1, p. 23 23.Research output: Contribution to journal › Article* › Academic › peer-review
-
Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials” [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233] (Contemporary Clinical Trials Communications (2023) 36, (S2451865423001795), (10.1016/j.conctc.2023.101233))
Hollander, B. D., Rothuizen-Lindenschot, M., Geertjens, L., Vaz, F. M., Brands, M. M., le, H. L., van Eeghen, A. M., van de Ven, P. M., Cornel, M. C., Jacobs, B. A. W., Bruining, H. & van Karnebeek, C. D., Apr 2024, In: Contemporary Clinical Trials Communications. 38, p. 101264 101264.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Mechanism-based interventions for ASD cannot be implemented using conventional trial designs
Sprengers, J. J., Geertjens, L. & Bruining, H., Feb 2024, In: Autism research. 17, 2, p. 202-203 2 p.Research output: Contribution to journal › Letter* › Academic › peer-review
- All publications